<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medparasitology</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская паразитология и паразитарные болезни</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Parasitology and Parasitic Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0025-8326</issn><issn pub-type="epub">2713-1777</issn><publisher><publisher-name>Научно-образовательный паразитологический центр им. П.Г. Сергиева</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33092/0025-8326mp2025.1.24-31</article-id><article-id custom-type="edn" pub-id-type="custom">GTKQMR</article-id><article-id custom-type="elpub" pub-id-type="custom">medparasitology-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Показатели функций гепатобилиарной системы у больных хроническим описторхозом с генетической предрасположенностью к развитию ишемической болезни сердца</article-title><trans-title-group xml:lang="en"><trans-title>Indicators of the functions of the hepatobiliary system in patients with chronic opisthrochisis with genetic predisposition to the development of ischemic heart disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бакштановская</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakshtanovskaya</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Тюмень</p></bio><bio xml:lang="en"><p>Tyumen</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Степанова</surname><given-names>К. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Stepanova</surname><given-names>K. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Тюмень</p></bio><bio xml:lang="en"><p>Tyumen</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Степанова</surname><given-names>Т. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Stepanova</surname><given-names>T. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Тюмень</p></bio><bio xml:lang="en"><p>Tyumen</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Озерова</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ozerova</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Тюмень</p></bio><bio xml:lang="en"><p>Tyumen</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зматракова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zmatrakova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Тюмень</p></bio><bio xml:lang="en"><p>Tyumen</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное бюджетное учреждение науки «Тюменский научно-исследовательский институт краевой инфекционной патологии» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tyumen Infection Pathology Research Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>21</day><month>04</month><year>2026</year></pub-date><volume>0</volume><issue>1</issue><fpage>24</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Научно-образовательный паразитологический центр им. П.Г. Сергиева, 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Научно-образовательный паразитологический центр им. П.Г. Сергиева</copyright-holder><copyright-holder xml:lang="en">Научно-образовательный паразитологический центр им. П.Г. Сергиева</copyright-holder><license xlink:href="https://www.medparasitology.com/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://www.medparasitology.com/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://www.medparasitology.com/jour/article/view/7">https://www.medparasitology.com/jour/article/view/7</self-uri><abstract><p>Для оценки влияния генетических особенностей, обеспечивающих предрасположенность к развитию ишемической болезни сердца, на реактивность гепатобилиарной системы при описторхозной инвазии проведено исследование биохимических показателей в подгруппах больных хроническим описторхозом с наличием и отсутствием мутаций в соответствущих локусах.</p><p>Обнаружено, что наличие мутации в локусе rs133304 гена CDKN 2A/2B увеличивает отклонения активности ГГТ от уровня здоровых лиц, вызываемые описторхозной инвазией, по-видимому, усугубляя нарушения процесса желчеотделения, и замедляет нормализацию интегрального показателя состояния гепатоцитов – билирубина – после лечения, при этом способствует снижению концентрации холестерина и повышению концентрации глюкозы в процессе лечения. Наличие редкого аллеля в локусе rs17602729 гена AMPD1, напротив, оказывает протективный эффект на процесс желчеотделения при ХО (судя по активности ГГТ и ЩФ), а также сглаживает изменения показателей в процессе терапии. Наличие мутантного аллеля в локусе rs133304 гена HIF1A предотвращает повышение концентрации билирубина и глюкозы, ускоряет нормализацию активности ГГТ после терапии, что можно считать положительным эффектом при ХО, но не влияет на повышение активности ЩФ в первые дни после лечения, отражающее сохранение затруднений в желчеотделении. Мутация в локусе rs3025058 гена MMP3 оказывает некоторое положительное влияние на динамику изменений аминотрансфераз и уровней билирубина и холестерина в процессе лечения, но способствует повышению уровня глюкозы после терапии.</p></abstract><trans-abstract xml:lang="en"><p>To assess the influence of genetic features that provide a predisposition to the development of coronary heart disease on the reactivity of the hepatobiliary system in opisthorchiasis invasion, a study of biochemical parameters was conducted in subgroups of patients with chronic opisthorchiasis with and without mutations in the corresponding loci. It was found that the presence of a mutation in the rs133304 locus of the CDKN 2A/2B gene increases deviations in GGT activity from the level of healthy individuals caused by opisthorchiasis invasion, apparently aggravating bile secretion disorders, and slows down the normalization of the integral indicator of the state of hepatocytes – bilirubin – after treatment, while contributing to a decrease in cholesterol concentration and an increase in glucose concentration during treatment. The presence of a rare allele in the rs17602729 locus of the AMPD1 gene, on the contrary, has a protective effect on the process of bile secretion in CO (judging by the activity of GGT and ALP), and also smooths out changes in the parameters during therapy. The presence of a mutant allele in the rs133304 locus of the HIF1A gene prevents an increase in the concentration of bilirubin and glucose, accelerates the normalization of GGT activity after therapy, which can be considered a positive effect in CO, but does not affect the increase in ALP activity in the first days after treatment, reflecting the persistence of difficulties in bile secretion. Mutation in the rs3025058 locus of the MMP3 gene has some positive effect on the dynamics of changes in aminotransferases and bilirubin and cholesterol levels during treatment, but contributes to an increase in glucose levels after therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический описторхоз</kwd><kwd>полиморфизмы</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>биохимические показатели</kwd><kwd>гепатобилиарная система</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic opisthorchiasis</kwd><kwd>polymorphisms</kwd><kwd>ischemic heart disease</kwd><kwd>biochemical parameters</kwd><kwd>disorders of bile secretion</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бакштановская И.В., Степанова К.Б., Озерова А.Н., Степанова Т.Ф., Зматракова Е.А. Показатели функций гепатобилиарной системы у больных хроническим описторхозом с генетической предрасположенностью к нарушениям липидного обмена // Медицинская паразитология и паразитарные болезни. 2023; 4: 22-29.</mixed-citation><mixed-citation xml:lang="en">Bakshtanovskaya I.V., Stepanova K.B., Ozerova A.N., Stepanova T.F., Zmatrakova E.A. Indicators of hepatobiliary system functions in patients with chronic opisthorchiasis with a genetic predisposition to lipid metabolism disorders // Med parasitol (Mosk). 2023; 4: 22-29. (in Russian)] DOI: 10.33092/0025-8326mp2023.4.22-29.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Степанова Т.Ф. Описторхоз: новые взгляды на инвазионную болезнь, основы клинической реабилитации, методологию крупномасштабных оздоровительных работ. Тюмень: Изд-во ТюмГУ. 2002: 196</mixed-citation><mixed-citation xml:lang="en">Stepanova T.F. Opisthorchiasis: new views on the invasive disease, the basics of clinical rehabilitation, the methodology of largescale recreational work. Tyumen.2002: 196 (in Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Бакштановская И.В., Степанова К.Б., Кальгина Г.А., Степанова Т.Ф. Взаимосвязи биохимических и иммунологических показателей у больных хроническим описторхозом // Медицинская паразитология и паразитарные болезни. 2018; 2: 13-19.</mixed-citation><mixed-citation xml:lang="en">Bakshtanovskaya I.V., Stepanova K.B., Kal’gina G.A., Stepanova T.F. Relationships between biochemical and immunological parameters in patients with chronic opisthorchiasis // Med parasitol (Mosk). 2018; 2: 13-19. (in Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Григорьева И.Н. Описторхоз: традиции и инновации // Экспериментальная и клиническая гастроэнтерология. 2012: 4: 54-59.</mixed-citation><mixed-citation xml:lang="en">Grigorieva I.N. Opisthorchiasis: traditions and innovations. Experimental and clinical gastroenterology. 2012: 4: 54-59. (in Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Han D., Zhang H., Liu S., Zhuang L., Zhao Z., Ding H., Xin Y. Association between the LRP5 rs556442 gene polymorphism and the risks of NA-FLD and CHD in a Chinese Han population // BMC gastroenterology, 2022; 22(1): 305. DOI:10.1186/s12876-022-02385-9.</mixed-citation><mixed-citation xml:lang="en">Han D., Zhang H., Liu S., Zhuang L., Zhao Z., Ding H., Xin Y. Association between the LRP5 rs556442 gene polymorphism and the risks of NA-FLD and CHD in a Chinese Han population // BMC gastroenterology, 2022; 22(1): 305. DOI:10.1186/s12876-022-02385-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Miura T., Kouzu H., Tanno M., Tatekoshi Y., Kuno A. Role of AMP deaminase in diabetic cardiomyopathy // Mol Cell Biochem. 2024; 479(12): 3195-3211. DOI: 10.1007/s11010-024-04951-z.</mixed-citation><mixed-citation xml:lang="en">Miura T., Kouzu H., Tanno M., Tatekoshi Y., Kuno A. Role of AMP deaminase in diabetic cardiomyopathy // Mol Cell Biochem. 2024; 479(12): 3195-3211. DOI: 10.1007/s11010-024-04951-z.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Feng A.F., Liu Z.H., Zhou S.L., Zhao S.Y., Zhu Y.X., Wang H.X. Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis // BMC Cardiovasc Disord. 2017; 17 (1): 174. DOI: 10.1186/s12872-017-0608-0.</mixed-citation><mixed-citation xml:lang="en">Feng A.F., Liu Z.H., Zhou S.L., Zhao S.Y., Zhu Y.X., Wang H.X. Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: a meta-analysis // BMC Cardiovasc Disord. 2017; 17 (1): 174. DOI: 10.1186/s12872-017-0608-0.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tandelilin A.A., Hirase T., Hudoyo A.W., et al. AMPD1 regulates mTORC1-p70 S6 kinase axis in the control of insulin sensitivity in skeletal muscle // BMC Endocr Disord. 2015; 15: 11. DOI: 10.1186/s12902-015-0010-9.</mixed-citation><mixed-citation xml:lang="en">Tandelilin A.A., Hirase T., Hudoyo A.W., et al. AMPD1 regulates mTORC1-p70 S6 kinase axis in the control of insulin sensitivity in skeletal muscle // BMC Endocr Disord. 2015; 15: 11. DOI: 10.1186/s12902-015-0010-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tibaut M., Naji F., Petrovič D. Association of myocardial infarction with CDKN2B antisense RNA 1 (CDKN2B-AS1) rs1333049 polymorphism in slovenian subjects with type 2 diabetes mellitus // Genes (Basel). 2022; 13(3): 526. DOI: 10.3390/genes13030526.</mixed-citation><mixed-citation xml:lang="en">Tibaut M., Naji F., Petrovič D. Association of myocardial infarction with CDKN2B antisense RNA 1 (CDKN2B-AS1) rs1333049 polymorphism in slovenian subjects with type 2 diabetes mellitus // Genes (Basel). 2022; 13(3): 526. DOI: 10.3390/genes13030526.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao J., Wu X., Nie S., et al. Association of CDKN2B-AS1 rs1333049 with brain diseases: a casecontrol study and a metaanalysis // Clin Psychopharmacol Neurosci. 2017; 15 (1): 53-58. DOI: 10.9758/cpn.2017.15.1.53.</mixed-citation><mixed-citation xml:lang="en">Zhao J., Wu X., Nie S., et al. Association of CDKN2B-AS1 rs1333049 with brain diseases: a casecontrol study and a metaanalysis // Clin Psychopharmacol Neurosci. 2017; 15 (1): 53-58. DOI: 10.9758/cpn.2017.15.1.53.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shen X., Li Y., He F., Kong J. LncRNA CD-KN2B-AS1 promotes cell viability, migration, and invasion of hepatocellular carcinoma via sponging miR-424-5p // Cancer Manag Res. 2020; 12: 6807-6819. DOI: 10.2147/CMAR.S240000.</mixed-citation><mixed-citation xml:lang="en">Shen X., Li Y., He F., Kong J. LncRNA CD-KN2B-AS1 promotes cell viability, migration, and invasion of hepatocellular carcinoma via sponging miR-424-5p // Cancer Manag Res. 2020; 12: 6807-6819. DOI: 10.2147/CMAR.S240000.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Xie F., Dong J., Zhu Y., Wang K., Liu X., Chen D., Meng Q. HIF1a Inhibitor Rescues Acute-on-Chronic Liver Failure // Ann Hepatol. 2019; 18(5): 757-764. DOI: 10.1016/j.aohep.2019.03.007.</mixed-citation><mixed-citation xml:lang="en">Xie F., Dong J., Zhu Y., Wang K., Liu X., Chen D., Meng Q. HIF1a Inhibitor Rescues Acute-on-Chronic Liver Failure // Ann Hepatol. 2019; 18(5): 757-764. DOI: 10.1016/j.aohep.2019.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mücke M.M., El Bali N., Schwarzkopf K.M., Uschner F.E., Kraus N., Eberle L., Mücke V.T., Bein J., Beyer S., Wild P.J., Schierwagen R., Klein S., Zeuzem S., Welsch C., Trebicka J., Brieger A. The role of hypoxia-inducible factor 1 alpha in acuteonchronic liver failure // Int J Mol Sci. 2024; 25(3): 1542. DOI: 10.3390/ijms25031542</mixed-citation><mixed-citation xml:lang="en">Mücke M.M., El Bali N., Schwarzkopf K.M., Uschner F.E., Kraus N., Eberle L., Mücke V.T., Bein J., Beyer S., Wild P.J., Schierwagen R., Klein S., Zeuzem S., Welsch C., Trebicka J., Brieger A. The role of hypoxia-inducible factor 1 alpha in acuteonchronic liver failure // Int J Mol Sci. 2024; 25(3): 1542. DOI: 10.3390/ijms25031542</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Li H.N., He T., Zha Y.J., Du F., Liu J., Lin H.R., Yang W.Z. HIF-1α rs11549465 C&gt;T polymorphism contributes to increased cancer susceptibility: Evidence from 49 studies // J Cancer. 2019; 10 (24): 5955-5963. DOI: 10.7150/jca.35716.</mixed-citation><mixed-citation xml:lang="en">Li H.N., He T., Zha Y.J., Du F., Liu J., Lin H.R., Yang W.Z. HIF-1α rs11549465 C&gt;T polymorphism contributes to increased cancer susceptibility: Evidence from 49 studies // J Cancer. 2019; 10 (24): 5955-5963. DOI: 10.7150/jca.35716.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pleskovič A., Letonja M.Š., Vujkovac A.C., Starčević J.N., Caprnda M., Curilla E., Mozos I., Kruzliak P., Prosecky R., Petrovič D. Matrix metalloproteinase-3 gene polymorphism (rs3025058) affects markers atherosclerosis in type 2 diabetes mellitus // Vasa. 2017; 46(5): 363-369. DOI:10.1024/0301-1526/a000637.</mixed-citation><mixed-citation xml:lang="en">Pleskovič A., Letonja M.Š., Vujkovac A.C., Starčević J.N., Caprnda M., Curilla E., Mozos I., Kruzliak P., Prosecky R., Petrovič D. Matrix metalloproteinase-3 gene polymorphism (rs3025058) affects markers atherosclerosis in type 2 diabetes mellitus // Vasa. 2017; 46(5): 363-369. DOI:10.1024/0301-1526/a000637.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shin H.P., Lee J.I., Jung J.H., Yim S.V., Kim H.J., Cha J.M., Park J.B., Joo K.R., Hwang J.S., Jang B.K. Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease // Dig Dis Sci. 2008; 53(3): 823-829. DOI :10.1007/s10620-007-9937-7.</mixed-citation><mixed-citation xml:lang="en">Shin H.P., Lee J.I., Jung J.H., Yim S.V., Kim H.J., Cha J.M., Park J.B., Joo K.R., Hwang J.S., Jang B.K. Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease // Dig Dis Sci. 2008; 53(3): 823-829. DOI :10.1007/s10620-007-9937-7.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W., Peng W.H., Lu L., Zhang R.Y., Zhang Q., Wang L.J., Chen Q.J., Shen W.F. Polymorphism on chromosome 9p21.3 contributes to earlyonset and severity of coronary artery disease in nondiabetic and type 2 diabetic patients // Chin Med J (Engl). 2011; 124(1): 66-71. DOI: 10.3901/jme.2011.08.066.</mixed-citation><mixed-citation xml:lang="en">Wang W., Peng W.H., Lu L., Zhang R.Y., Zhang Q., Wang L.J., Chen Q.J., Shen W.F. Polymorphism on chromosome 9p21.3 contributes to earlyonset and severity of coronary artery disease in nondiabetic and type 2 diabetic patients // Chin Med J (Engl). 2011; 124(1): 66-71. DOI: 10.3901/jme.2011.08.066.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Luo M., Li T., Sang H. The role of hypoxia-inducible factor 1α in hepatic lipid metabolism // J Mol Med (Berl). 2023; 101(5): 487-500. DOI: 10.1007/s00109-023-02308-5.</mixed-citation><mixed-citation xml:lang="en">Luo M., Li T., Sang H. The role of hypoxia-inducible factor 1α in hepatic lipid metabolism // J Mol Med (Berl). 2023; 101(5): 487-500. DOI: 10.1007/s00109-023-02308-5.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lu Y., Sui J., Liu Y., Li R., Ma L., Zhang X., Qin X., Li S. Association between hypoxia-inducible factor-1α gene polymorphisms and risk of chronic hepatitis B and hepatitis B virusrelated liver cirrhosis in a Chinese population: a retrospective casecontrol study // Gene. 2015; 564(1): 96-100. DOI: 10.1016/j.gene.2015.03.053.</mixed-citation><mixed-citation xml:lang="en">Lu Y., Sui J., Liu Y., Li R., Ma L., Zhang X., Qin X., Li S. Association between hypoxia-inducible factor-1α gene polymorphisms and risk of chronic hepatitis B and hepatitis B virusrelated liver cirrhosis in a Chinese population: a retrospective casecontrol study // Gene. 2015; 564(1): 96-100. DOI: 10.1016/j.gene.2015.03.053.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Norcia L.F., Watanabe E.M., Hamamoto Filho P.T., Hasimoto C.N., Pelafsky L., de Oliveira W.K., Sassaki L.Y. Polycystic liver disease: pathophysiology, diagnosis and treatment // Hepatic medicine: evidence and research, 2022; 14: 135-161. DOI: 10.2147/HMER.S377530.</mixed-citation><mixed-citation xml:lang="en">Norcia L.F., Watanabe E.M., Hamamoto Filho P.T., Hasimoto C.N., Pelafsky L., de Oliveira W.K., Sassaki L.Y. Polycystic liver disease: pathophysiology, diagnosis and treatment // Hepatic medicine: evidence and research, 2022; 14: 135-161. DOI: 10.2147/HMER.S377530.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
